The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II cancer vaccination trial with multiple peptides derived from novel oncoantigens against advanced esophageal cancer.
K. Kono
No relevant relationships to disclose
H. Iinuma
No relevant relationships to disclose
Y. Akutsu
No relevant relationships to disclose
H. Tanaka
No relevant relationships to disclose
N. Hayashi
No relevant relationships to disclose
Y. Uchikado
No relevant relationships to disclose
T. Noguchi
No relevant relationships to disclose
H. Fujii
No relevant relationships to disclose
R. Fukushima
No relevant relationships to disclose
H. Matsubara
No relevant relationships to disclose
K. Hirakawa
No relevant relationships to disclose
H. Baba
No relevant relationships to disclose
S. Natsugoe
No relevant relationships to disclose
S. Kitano
No relevant relationships to disclose
K. Yoshida
Employment or Leadership Position - OncoTherapy Science
T. Tsunoda
Employment or Leadership Position - OncoTherapy Science
Y. Nakamura
Stock Ownership - OncoTherapy Science